Serum Biomarker Profiles in Acute Ischemic Stroke

The sera of patients with AIS and transient ischemic attack (TIA), which were collected within 2 weeks after disease onset, were obtained from Chiba Prefectural Sawara Hospital and Chiba Rosai Hospital. The stroke subtypes were determined according to the criteria of the Trial of ORG 10172 in Acute Stroke Treatment classification system (34 (link)), and large-artery atherosclerosis and small-arterial occlusion (lacuna) were included as AIS or ischemic stroke. The sera of patients with DM and AMI were obtained from Chiba University Hospital and Kyoto University Hospital, respectively. The sera of patients with CKD were obtained from the Kumamoto cohort (35 (link), 36 (link)). The Department of Surgery, Toho University Hospital, collected sera from patients with EC, GC, CRC, lung cancer (LC), and mammary cancer (MC; 37 (link)) between June 2010 and February 2016, and all patients were followed up until July 2018 or death. EC was analyzed in 91 cases, GC was analyzed in 57 cases and CRC was analyzed in 113 cases, of which all cases were underwent radical surgery. Patients who underwent neoadjuvant chemotherapy and had a double cancer were excluded from the study. According to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma, 3d English Edition (Secondary Publication; 38 (link)), the numbers of patients with colorectal cancer were as follows: five patients in stage 0, 29 in stage I, 32 in stage II, 31 in stage III, and 16 in stage IV. In addition, the sera of healthy donors (HDs) were selected from people who underwent a medical checkup at Chiba University, Port Square Kashiwado Clinic, and Chiba Prefectural Sawara Hospital. Clinicopathological characteristics and prognoses were obtained retrospectively. Individuals with no history of cancer, autoimmune disease, or cerebrovascular disease and those without any abnormalities on cranial MRI were enrolled as HDs.
Serum samples of AIS, TIA, DM, CKD, and HD were collected at the time of hospital admission. Serum samples of the cancers were collected before treatment. All serum samples were centrifuged at 3,000 g for 10 min, and the supernatants were stored at −80°C until use. To preserve sample integrity, repeated freezing/thawing of serum samples was avoided.

Free full text: Click here

Li S.Y., Yoshida Y., Kubota M., Zhang B.S., Matsutani T., Ito M., Yajima S., Yoshida K., Mine S., Machida T., Hayashi A., Takemoto M., Yokote K., Ohno M., Nishi E., Kitamura K., Kamitsukasa I., Takizawa H., Sata M., Yamagishi K., Iso H., Sawada N., Tsugane S., Iwase K., Shimada H., Iwadate Y, & Hiwasa T. (2023). Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer. Frontiers in Cardiovascular Medicine, 10, 1042272.

Publication 2023

Abnormalities Acute stroke Anal carcinoma Arterial occlusion Artery Atherosclerosis Autoimmune disease Cancer Cerebrovascular disease Colorectal cancer Cranial Donors Ischemic stroke Japanese Lung cancer Mammary cancer Neoadjuvant chemotherapy Org 10172 Patients Prognoses Serum Serum cancers Stroke Surgery Transient ischemic attack

Corresponding Organization : Toho University

Other organizations : Chiba Prefectural Sawara High School, Chiba Cerebral and Cardiovascular Center, Teikyo University Chiba Medical Center, International University of Health and Welfare, Shiga University of Medical Science, Kyoto University, Chiba Rosai Hospital, University of Tsukuba, Keio University, Osaka University

Top 5 similar protocols

Variable analysis

independent variables

Disease type (AIS, TIA, DM, CKD, EC, GC, CRC, LC, MC)

dependent variables

Serum samples

control variables

Time of sample collection (within 2 weeks after disease onset for AIS and TIA, before treatment for cancers)
Exclusion criteria (patients who underwent neoadjuvant chemotherapy, had a double cancer)
Healthy donors (no history of cancer, autoimmune disease, or cerebrovascular disease, and no abnormalities on cranial MRI)

controls

Positive control: Healthy donors (HDs)
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!